Bank Of New York Mellon Corp Rapt Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $1.34 Million - $2.03 Million	82,423 New	82,423 $1.63 Million
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $155,982 - $264,545	8,685 Added 12.07%	80,652 $1.94 Million
Q2 2022 Aug 15, 2022	BUY	$10.26 - $23.59 $63,406 - $145,786	6,180 Added 9.39%	71,967 $1.31 Million
Q1 2022 May 11, 2022	SELL	$17.02 - $40.22 $3,131 - $7,400	-184 Reduced 0.28%	65,787 $1.45 Million
Q4 2021 Feb 11, 2022	SELL	$29.5 - $39.5 $553,302 - $740,862	-18,756 Reduced 22.14%	65,971 $2.42 Million
Q3 2021 Nov 12, 2021	BUY	$29.86 - $39.47 $407,350 - $538,449	13,642 Added 19.19%	84,727 $2.63 Million
Q2 2021 Aug 11, 2021	BUY	$17.99 - $40.02 $447,555 - $995,617	24,878 Added 53.84%	71,085 $2.26 Million
Q1 2021 May 13, 2021	SELL	$16.0 - $24.46 $9,104 - $13,917	-569 Reduced 1.22%	46,207 $1.03 Million
Q4 2020 Feb 09, 2021	BUY	$15.89 - $40.87 $270,559 - $695,893	17,027 Added 57.24%	46,776 $923,000
Q3 2020 Nov 12, 2020	BUY	$21.6 - $37.5 $5,400 - $9,375	250 Added 0.85%	29,749 $957,000
Q2 2020 Aug 12, 2020	BUY	$14.16 - $32.85 $417,705 - $969,042	29,499 New	29,499 $856,000

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $24.9M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.